Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/MOG Antibody-Associated Disease

Neurological & Neuromuscular

MOG Antibody-Associated Disease (MOGAD) Clinical Trials

Also called MOGAD, MOG Antibody Disease, Anti-MOG Disease, MOG-IgG Associated Disorder, Myelin Oligodendrocyte Glycoprotein Antibody Disease, MOG-EM, Anti-MOG Encephalomyelitis

Myelin is the insulating coat that lets nerve signals travel quickly. Myelin oligodendrocyte glycoprotein, or MOG, is a protein on the outer surface of that coat in the brain, spinal cord and optic nerves. In MOGAD the immune system makes antibodies against MOG and inflammation strips the myelin where they bind.

In plain words, MOG antibody-associated disease is a rare condition in which the immune system attacks the protective coating of nerves. Attacks can hit the nerves of the eyes, spinal cord or brain and cause vision loss, weakness or numbness.

Get an email when new MOG Antibody-Associated Disease trials open or the FDA decides. Get alerts

MOG Antibody-Associated Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 12 studies with no phase, like observational studies.

FDA review1

Enspryng, Jan 10, 2027

FDA-approved medicines0

No medicine's current FDA label names MOG Antibody-Associated Disease yet.

MOG Antibody-Associated Disease has no FDA-approved medicines, 18 open or active clinical trials (14 recruiting), and a pending FDA decision on Enspryng, due Jan 10, 2027.

Labels checked October 21, 2026.Download the data

More about MOG Antibody-Associated Disease

The optic nerves are the favorite target, which is why vision problems lead the list of symptoms, followed by the spinal cord and, especially in children, the brain itself. Attacks often improve with treatment, but each one can leave lasting damage, and about a third of people with optic neuritis and half of those with spinal cord attacks recover fully.

Keep reading about MOG Antibody-Associated Disease

For years people with MOGAD were told they had multiple sclerosis, NMOSD, ADEM or unexplained optic neuritis, because the attacks look alike on an MRI. A live cell-based assay for the MOG antibody, available since 2017, changed that; older ELISA tests are not reliable enough to make the diagnosis.

Telling them apart is important because MOGAD, MS and aquaporin-4 NMOSD are driven by different immune mechanisms and respond to different drugs, and NORD notes that MS treatments are not recommended in MOGAD. The antibody can fade over time and may be undetectable during remission, so a negative test early in the illness does not always rule it out.

Doctors treat an attack with high-dose intravenous steroids for 3 to 5 days, often followed by a slow steroid taper to prevent a rebound, and add plasma exchange or intravenous immunoglobulin (IVIG) when recovery is slow. Preventing the next attack is the open question. The medicines used in the United States, mycophenolate, rituximab, azathioprine and repeated IVIG, are all borrowed from other conditions and supported only by small observational studies, and there is no agreement on whether to start them after a first attack.

What are the symptoms of MOG Antibody-Associated Disease?

These are common symptoms of MOG Antibody-Associated Disease, and how strong they are varies from person to person.

  • Blurred or lost vision in one or both eyes, usually with pain on eye movement (optic neuritis)
  • Loss of color vision
  • Weakness or paralysis in the legs or arms from spinal cord inflammation (transverse myelitis)
  • Numbness or loss of sensation
  • Bladder or bowel problems, including being unable to empty the bladder
  • Confusion, drowsiness or seizures from brain inflammation, the usual pattern in young children (ADEM)

Who gets MOG Antibody-Associated Disease?

MOGAD affects children and adults of all ages. In children it often appears as ADEM, a sudden episode of brain inflammation, and in many of those children the antibody disappears within a year and never returns. Optic neuritis, often in both eyes at once, and spinal cord inflammation are the other common patterns. Some studies find patients are younger and more often male than those with aquaporin-4 NMOSD; others find no difference. In a 2016 study, 80% of people who tested positive for the antibody went on to have more than 1 attack, and there is still no reliable way to predict who will.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How MOG Antibody-Associated Disease is diagnosed

MOGAD is an autoimmune disease, not an inherited one; the diagnostic test is a blood test for the MOG antibody, not a genetic test.

Trusted MOG Antibody-Associated Disease resources

Reputable organizations and medical references for learning more about MOG Antibody-Associated Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for MOG Antibody-Associated Disease

Use this MOG Antibody-Associated Disease clinical trial finder to see the 14 studies recruiting patients and 4 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 9 test a treatment and 9 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Enspryng (satralizumab), due January 10, 2027. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

18 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT07202494

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

Intervention: Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)

Sponsor: Assistance Publique Hopitaux De Marseille

The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging. It leverages advanced multiparametric brain and spinal cord imaging at high (3T) and ultra-high m...

Ages 18 Years to 90 Years1 location
Started May 2025Updated 2 days agoEst. May 2030 (~3y 5m)
RecruitingTreatment trialPhase 3Recently updatedNCT07917247

Safety and Efficacy of Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Intervention: Secukinumab, Mycophenolate mofetil (MMF)

Sponsor: Chinese PLA General Hospital

The goal of this clinical trial is to evaluate the safety and efficacy of secukinumab versus mycophenolate mofetil in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Ages 6 Years+1 location
Started Nov 2026Updated 3 days agoEst. May 2028 (~1y 5m)
Not yet recruitingTreatment trialRecently updatedNCT07902479

Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health

Intervention: Blood sampling and multi-omic profiling

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

The goal of this observational study is to learn why some families have several members with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or MOG antibody-associated disease (MOGAD). These diseases happen when the immune system attacks the brain, optic ...

Ages 15 Years+
Expected to start Nov 2026Updated 2 weeks agoEst. Apr 2029 (~2y 5m)
Not yet recruitingTreatment trialPhase 1/2Recently updatedNCT07804004

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

Intervention: CTX112

Sponsor: CRISPR Therapeutics

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spec...

Ages 18 Years to 70 Years
Expected to start Nov 2026Updated 1 month agoEst. Dec 2029 (~3y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT06617962

Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders

Intervention: CBA method of live cells and fixed cells

Sponsor: Huashan Hospital

Anti-myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD) is a rare inflammatory autoimmune disease. In addition, since the international MOGAD group proposed live-cell based assays for MOGAD diagnosis in 2023, there are still no real-world cohort validation studi...

Ages 18 Years+1 location
Started Nov 2024Updated 2 months agoEst. Dec 2025
Find MOG Antibody-Associated Disease trials near you, ranked by distance →
Active trial locations1 city in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Early Phase 1
Phase 1
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about MOG Antibody-Associated Disease trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a MOG Antibody-Associated Disease foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

MOG Antibody-Associated Disease patient communities

Facebook groups, Reddit communities and YouTube channels where MOG Antibody-Associated Disease patients, caregivers and advocacy groups talk.

Companies developing MOG Antibody-Associated Disease treatments

Drugmakers that list MOG Antibody-Associated Disease in their rare disease portfolio, 2 in all.

Questions people ask about MOG Antibody-Associated Disease